Bystolic: Advanced Beta-Blocker Therapy for Hypertension Control
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.14 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $84.28 $65.36 (22%) | 🛒 Add to cart |
| 90 | $0.99 | $126.42 $89.44 (29%) | 🛒 Add to cart |
| 120 | $0.94 | $168.56 $112.66 (33%) | 🛒 Add to cart |
| 180 | $0.89 | $252.84 $160.82 (36%) | 🛒 Add to cart |
| 270 | $0.86
Best per pill | $379.26 $232.20 (39%) | 🛒 Add to cart |
Synonyms | |||
Bystolic (nebivolol) is a beta-adrenergic blocking agent indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. This cardioselective beta-blocker offers a unique hemodynamic profile, combining beta-1 receptor blockade with vasodilatory properties through modulation of the endothelial L-arginine/nitric oxide pathway. Its pharmacological profile makes it a valuable option in the management of high blood pressure, particularly for patients who may benefit from its favorable side effect characteristics and once-daily dosing regimen.
Features
- Active ingredient: Nebivolol hydrochloride
- Available in tablet strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg
- Beta-1 cardioselective adrenergic receptor blocker
- Vasodilatory properties via endothelial nitric oxide potentiation
- Once-daily oral administration
- Bioavailability: Approximately 12% in fast metabolizers, 96% in slow metabolizers
- Half-life: Approximately 12 hours in extensive metabolizers
- Protein binding: Approximately 98%
- Metabolism: Hepatic via CYP2D6
Benefits
- Effectively lowers both systolic and diastolic blood pressure through dual mechanism of action
- Demonstrates cardioselectivity at therapeutic doses, minimizing pulmonary and metabolic effects
- Vasodilatory properties may improve peripheral blood flow compared to traditional beta-blockers
- Favorable metabolic profile with neutral effects on glucose and lipid metabolism
- Once-daily dosing enhances patient adherence to treatment regimen
- Generally well-tolerated side effect profile compared to older beta-blockers
Common use
Bystolic is primarily prescribed for the management of hypertension. It is suitable for both newly diagnosed patients and those requiring a change in their antihpertensive regimen. The medication may be particularly appropriate for patients who experience adverse effects with traditional beta-blockers, such as fatigue or sexual dysfunction, though individual responses vary. Clinical studies have demonstrated its efficacy across diverse patient populations, including those with comorbid conditions, though specific considerations apply in certain clinical scenarios as detailed in the precautions section.
Dosage and direction
The recommended starting dose of Bystolic is 5 mg once daily, with or without food. Dosage may be increased at 2-week intervals to achieve optimal blood pressure control. The effective dosage range is 5 mg to 40 mg daily. Most patients respond to doses between 5 mg and 20 mg daily. For patients with severe renal impairment (CrCl less than 30 mL/min) or moderate hepatic impairment, the recommended initial dose is 2.5 mg once daily. Dose escalation should be performed cautiously in these populations. Tablets should be swallowed whole and not crushed or chewed. Blood pressure response should be monitored regularly, particularly after dosage adjustments.
Precautions
Patients should be monitored for signs and symptoms of excessive bradycardia. Abrupt discontinuation should be avoided, as this may precipitate angina or myocardial infarction in patients with coronary artery disease. Use with caution in patients with compensated heart failure, as beta-blockers may precipitate cardiac decompensation. Diabetic patients should be monitored closely, as beta-blockers may mask some symptoms of hypoglycemia. Patients with bronchospastic disease should generally not receive beta-blockers; if necessary, Bystolic may be used with extreme caution due to its relative cardioselectivity. Peripheral vascular disease patients may experience exacerbation of symptoms. Ophthalmological monitoring is recommended for patients wearing contact lenses, as beta-blockers may reduce tear production.
Contraindications
Bystolic is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is present), severe hepatic impairment (Child-Pugh class C), and hypersensitivity to nebivolol or any component of the formulation. The medication should not be used in patients with asthma or bronchospastic diseases who are not receiving concomitant bronchodilator therapy. Concomitant use with floctafenine or sultopride is contraindicated.
Possible side effects
The most common adverse reactions (occurring in ≥2% of patients) include headache, fatigue, dizziness, diarrhea, nausea, insomnia, chest pain, bradycardia, dyspnea, rash, and peripheral edema. Less common but potentially serious side effects may include worsening heart failure, heart block, bronchospasm, masking of hypoglycemia symptoms in diabetics, and Raynaud’s phenomenon. Some patients may experience central nervous system effects such as depression or vivid dreams. Sexual dysfunction, though less frequent than with traditional beta-blockers, may occur. Laboratory abnormalities may include increased blood urea nitrogen and triglycerides.
Drug interaction
Bystolic may interact with other drugs that slow AV conduction, such as digoxin, verapamil, and diltiazem, potentially leading to excessive bradycardia. Concomitant use with other antihypertensive agents may produce additive hypotensive effects. CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) may increase nebivolol concentrations. Drugs that reduce heart rate and contractility, including certain calcium channel blockers and antiarrhythmics, may potentiate these effects. Concomitant use with clonidine may potentiate rebound hypertension upon discontinuation of either drug. NSAIDs may diminish the antihypertensive effect of nebivolol.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining stable blood pressure control. Healthcare providers should educate patients about the importance of adherence and establish strategies to minimize missed doses.
Overdose
Symptoms of overdose may include severe bradycardia, hypotension, heart failure, bronchospasm, and hypoglycemia. In case of suspected overdose, medical attention should be sought immediately. Treatment is supportive and symptomatic. Bradycardia may be treated with atropine; if unresponsive, isoproterenol or cardiac pacing may be considered. Hypotension may require vasopressors such as dopamine or dobutamine. Bronchospasm may be treated with bronchodilators. Hemodialysis is unlikely to be effective due to high protein binding. Blood glucose should be monitored in diabetic patients.
Storage
Store Bystolic tablets at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs or by mixing with undesirable substance and placing in sealed container.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient circumstances. Patients should not alter their medication regimen without consulting their healthcare provider. The prescribing information included here may not include all possible uses, directions, precautions, or interactions. Always refer to the official prescribing information for complete details.
Reviews
Clinical studies have demonstrated Bystolic’s efficacy in reducing blood pressure with a generally favorable tolerability profile. In randomized controlled trials, nebivolol showed significant reductions in both systolic and diastolic blood pressure compared to placebo. Many clinicians note its utility in patients who cannot tolerate older beta-blockers due to side effects. Some studies suggest potential benefits beyond blood pressure control, including improved endothelial function, though these effects require further investigation. Patient-reported outcomes often indicate better quality of life measures compared to traditional beta-blockers, particularly regarding energy levels and sexual function. However, individual responses vary, and careful patient selection remains important.